Proactive Investors - Run By Investors For Investors

NeuroRx aims to tackle suicide by treating bipolar depression with new therapy

NeuroRx Inc CEO Dr. Jonathan Javitt tells Proactive Investors the privately-held clinical stage biopharma company is focused on preventing suicide by treating bipolar depression with its small molecule oral drug called NRX-101.

Dr. Javitt says NRX-101 was recently granted Breakthrough Therapy Designation by the FDA for this indication, and is now entering Phase 3 clinical studies with the drug.

 
View full Neuro profile View Profile

NeuroRx Timeline

Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use